VistaGen Therapeutics Announces Appointment of Maggie FitzPatrick to its Board of Directors
July 22 2021 - 8:00AM
VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical
company committed to developing a new generation of medicines with
the potential to go beyond the current standard of care for
anxiety, depression and other central nervous system (“CNS”)
disorders, today announced the appointment of Maggie FitzPatrick to
its Board of Directors (“Board”), replacing Dr. Brian J. Underdown
who recently retired from the Board.
“Maggie is a highly-regarded public affairs
strategist with extensive experience developing and executing
multiple high impact customer-focused marketing communications
initiatives for some of the world’s largest and most successful
companies, including Johnson & Johnson and Cigna,” said Shawn
Singh, Chief Executive Officer of VistaGen. “Her expertise in
positioning companies and products through public relations,
marketing and digital media campaigns will be valuable both before
and after commercial launch of our product candidates. We are
excited to have Maggie on our Board as we continue to progress
through key stages of our corporate growth with a steadfast
commitment to improving mental health and well-being for
individuals all around the world.”
Ms. FitzPatrick is a globally recognized
corporate affairs executive who has been honored with several
prestigious awards, including the Washington Business Journal’s
C-Suite Executive of the Year Class (2019), PR Week’s Top 50 Most
Powerful People in PR (2015) and PR Week’s Hall of Femme (2019).
Recently, she served as a member of the Exelon Corporation
executive committee. At Exelon, she led communications, customer
engagement, digital and crisis reputation management and
philanthropy for the Fortune 100 Company. Prior to Exelon, Maggie
served as Global Chief Communications Officer and led public
affairs at Johnson & Johnson, the world's largest and most
broadly-based healthcare company. She directed a global team of
more than 425 professionals and oversaw the modernization and
transformation of Johnson & Johnson's global public affairs,
reputation management and digital content programs. She and her
team implemented a customer-focused strategy to strengthen
engagement initiatives across the company’s 265 operating
companies, across sixty countries. Prior to Johnson & Johnson,
Maggie served as Global Chief Communication Officer and President
of the Foundation at Cigna, where she led a corporate re-branding
effort and directed marketing communications for the company’s
global expansion. Previous to that, Maggie was Executive Vice
President at APCO Worldwide, a global public affairs and strategic
communications consultancy. In this role she counseled executives
on major global reputation efforts for notable industry leaders
such as eBay and United Airlines, among others. Maggie also serves
on the board of the Southeast Tennis and Learning Center in
Washington, D.C. In 2020, she was appointed by DC Mayor Muriel
Bowser to serve as a Commissioner on the DC Commission on the Arts
and Humanities.
Ms. FitzPatrick holds a B.A. in English and
Policy Studies from Syracuse University, and an M.A. in Public
Policy from The George Washington University. In 2018, she
completed the Harvard Business School program for corporate
directors.
Jon S. Saxe, Chairman of the Board, added, “On
behalf of the Company and its stockholders, I would like to extend
a heartfelt thank you to Dr. Underdown for his long service to our
Board and for his contributions in helping grow the company. We
wish him the very best in his retirement and all of his future
endeavors. I would also like to welcome Maggie to the VistaGen
Board.”
About VistaGenVistaGen
Therapeutics is a biopharmaceutical company committed to developing
and commercializing innovative medicines with the potential to go
beyond the current standard of care for anxiety, depression, and
other CNS disorders. Each of VistaGen's three drug candidates has a
differentiated potential mechanism of action, has been
well-tolerated in all clinical studies to date, and has therapeutic
potential in multiple CNS markets. For more information, please
visit www.VistaGen.com and connect with VistaGen on
Twitter, LinkedIn, and Facebook.
Forward Looking StatementsThis
press release contains certain forward-looking statements within
the meaning of the federal securities laws. These forward-looking
statements involve known and unknown risks that are difficult to
predict and include all matters that are not historical facts. In
some cases, you can identify forward-looking statements by the use
of words such as “may,” “could,” “expect,” “project,” “outlook,”
“strategy,” “intend,” “plan,” “seek,” “anticipate,” “believe,”
“estimate,” “predict,” “potential,” “strive,” “goal,” “continue,”
“likely,” “will,” “would” and variations of these terms and similar
expressions, or the negative of these terms or similar expressions.
Such forward-looking statements are necessarily based upon
estimates and assumptions that, while considered reasonable by us
and our management, are inherently uncertain. Our actual results or
developments may differ materially from those projected or implied
in these forward-looking statements. Factors that may cause such a
difference are fully discussed in the section entitled "Risk
Factors" in our most recent Annual Report on Form 10-K for the
fiscal year ended March 31, 2021, as well as discussions of
potential risks, uncertainties, and other important factors in our
other filings with the U.S. Securities and Exchange Commission
(SEC). Our SEC filings are available on the SEC’s website at
www.sec.gov. You should not place undue reliance on these
forward-looking statements, which apply only as of the date of this
press release and should not be relied upon as representing our
views as of any subsequent date. We explicitly disclaim any
obligation to update any forward-looking statements, other than as
may be required by law. If we do update one or more forward-looking
statements, no inference should be made that we will make
additional updates with respect to those or other forward-looking
statements.
VistaGen Company ContactsMedia:Mark
McPartlandPhone: (650) 577-3606Email: IR@vistagen.com
Investors:Mark FlatherPhone: (650) 577-3617Email:
mflather@vistagen.com
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Apr 2023 to Apr 2024